Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Projects and Technology
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Projects and Technology
    • Veterinary Medicine
      • Paccal Vet – Dog
      • Paccal Vet – Cat
    • Project Portfolio – Human Pharmaceuticals
      • Cantrixil
      • Apealea
    • XR Drug Delivery Platform
      • Advantages
      • Patent Protection
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

Press Releases
  • Regulatory Releases
  • All releases
2020
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Non Regulatory
December 29, 2020

Oasmia Secures Valuable IP Rights in Australia and Brazil

Non Regulatory
November 30, 2020

Invitation to presentation of Oasmia’s Q2 report on December 9

Non Regulatory
November 27, 2020

Oasmia appoints Robert Maiorana as acting CFO

Non Regulatory
November 3, 2020

Oasmia to present at Investival Showcase November 11-16

Non Regulatory
October 26, 2020

Oasmia Secures Important IP Rights

Non Regulatory
October 20, 2020

Oasmia to present at Bio Europe Digital on October 26-29

Non Regulatory
September 24, 2020

Oasmia to present at Penser’s cancer research day October 7

Non Regulatory
September 23, 2020

Oasmia to present at Penser’s Bolagsdag September 24

Non Regulatory
September 16, 2020

Oasmia to present at Sachs Associates’ 20th Annual Biotech in Europe Forum

Non Regulatory
September 1, 2020

Oasmia to present at Aktiedagen Digitalt on September 15

Non Regulatory
September 1, 2020

Invitation to presentation of Oasmia’s Q1 report 2020/2021 on September 9, 2020

Non Regulatory
August 31, 2020

Oasmia to present at Aktiedagen Digital on September 8

Non Regulatory
June 9, 2020

Invitation to presentation of Oasmia’s Year End Report 2019/2020 on June 18, 2020

Non Regulatory
June 8, 2020

Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK, The Swiss Group for Clinical Cancer Research for Evaluation of Docetaxel Micellar

Non Regulatory
June 5, 2020

Oasmia to present at Aktiespararna’s Småbolagsdagar on 10 June

Non Regulatory
June 2, 2020

Oasmia to present at Avanza Börsdag on 3 June 2020

Non Regulatory
June 1, 2020

Oasmia Pharmaceutical has entered into a settlement agreement in US class action

Non Regulatory
May 14, 2020

Oasmia Pharmaceutical announces poster presentation at American Society of Clinical Oncology 2020 annual meeting

Non Regulatory
April 21, 2020

Oasmia receives upfront payment of 20 MUSD from Elevar

Non Regulatory
March 23, 2020

Oasmia presents Q3 report through audiocast on March 27

Non Regulatory
March 9, 2020

Nomination committee in Oasmia for the 2020 AGM

Non Regulatory
January 30, 2020

Oasmia launches the ovarian cancer treatment drug Apealea® in Sweden, Denmark and Finland

Non Regulatory
January 9, 2020

Oasmia to present at Biotech Showcase in San Francisco

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

 

Take me there
Vivesto logo
  • About Us
  • Projects and Technology
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com